Amylyx selects GLP-1 antagonist AMX0318 as development candidate for post-bariatric hypoglycemia

Amylyx Pharmaceuticals, Inc.

AMX0318 is a long-acting GLP-1 receptor antagonist for post-bariatric hypoglycemia and other rare diseases.
Candidate identified through research collaboration with Gubra; Gubra eligible for >$50M in development and commercial milestones.
Handover of candidate triggers $4M milestone payment to Gubra; mid-single digit royalties on worldwide net sales.
Amylyx expects to initiate IND-enabling studies and file an IND for AMX0318, though no specific timeline was provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.